Nature Search

A group 3 medulloblastoma stem cell program is maintained by OTX2-mediated alternative splicing

Werbowetski-Ogilvie, Taylor and colleagues report a noncanonical role for OTX2 in regulating alternative splicing and controlling a stem cell and pro-tumorigenic splicing program in group 3 medulloblastoma.

Olivier Saulnier
Jamie Zagozewski
Tamra E. Werbowetski-Ogilvie
ResearchOpen Access18 Jul 2024
Nature Cell Biology

Volume: 26, P: 1233-1246
Author Correction: Failure of human rhombic lip differentiation underlies medulloblastoma formation

Liam D. Hendrikse
Parthiv Haldipur
Michael D. Taylor
Amendments and Corrections29 Nov 2022
Nature

Volume: 612, P: E12
Failure of human rhombic lip differentiation underlies medulloblastoma formation

Derailed differentiation of human-specific progenitors of the developing cerebellar rhombic lip is the cause of group 4 medulloblastoma, the most common childhood brain tumour.

Liam D. Hendrikse
Parthiv Haldipur
Michael D. Taylor
Research21 Sept 2022
Nature

Volume: 609, P: 1021-1028
Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma

The molecular mechanisms underlying MYC overexpression in group 3 medulloblastoma remain to be explored. Here, the authors highlight the involvement of the mitochondrial pyruvate carrier- SOD2 signalling pathway in the regulation of MYC protein abundance.

Emma Martell
Helgi Kuzmychova
Tanveer Sharif
ResearchOpen Access02 May 2023
Nature Communications

Volume: 14, P: 1-26
An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate

OTX2 promotes tumour growth in Group 3 medulloblastoma. Here, the authors show that OTX2 regulates PAX3 to induce neural de-differentiation and promote tumourigenesis in Group 3 medulloblastoma.

Jamie Zagozewski
Ghazaleh M. Shahriary
Tamra E. Werbowetski-Ogilvie
ResearchOpen Access20 Jul 2020
Nature Communications

Volume: 11, P: 1-18
Cross-species analysis of SHH medulloblastoma models reveals significant inhibitory effects of trametinib on tumor progression

Stephanie Borlase
Alexandria DeCarlo
Tamra E. Werbowetski-Ogilvie
ResearchOpen Access19 Sept 2023
Cell Death Discovery

Volume: 9, P: 1-13
Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression

RNA sequencing of MEK inhibitor (selumetinib)-treated tumors reveals an upregulation of the JAK/STAT3 pathway, with combinatorial therapeutic strategies of JAK/STAT3 inhibitors and selumetinib investigated for the SHH subgroup of medulloblastoma.

Jamie Zagozewski
Stephanie Borlase
Tamra E. Werbowetski-Ogilvie
ResearchOpen Access14 Jul 2022
Communications Biology

Volume: 5, P: 1-17

Search

Filter By:

A group 3 medulloblastoma stem cell program is maintained by OTX2-mediated alternative splicing

Author Correction: Failure of human rhombic lip differentiation underlies medulloblastoma formation

Failure of human rhombic lip differentiation underlies medulloblastoma formation

Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma

An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate

Cross-species analysis of SHH medulloblastoma models reveals significant inhibitory effects of trametinib on tumor progression

Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression

Search

Quick links